anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This pragmatic trial aims to assess the impact of Eat Well participation for diabetes patients at risk of food insecurity. Eligible patients will receive gift/debit cards for the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-approved fruits and vegetables and be assigned to either receive the card for up to 12 months or not. Random assignment will occur using a 2 to 1 treatment to control allocation ratio. Both treatment and control groups will receive curated diabetes educational materials. The study will assess the impact of the intervention on clinical factors such as glycemic control, weight, BMI, lipids, medication adherence, medication number, blood pressure, and utilization up to 18 months pre, during, and post program enrollment using data from clinical visits. The primary analysis of interest will be differences in HbA1c measurements and ED visits between the Eat Well and control groups at 12 months of program participation, with further evaluation of differences at 12 months post-program completion.
Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated stilbene to a herpes virus-infected site. The present inventi on also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of reducing the cytopathic effect o f HSV on mammalian cells. The method involves administering resveratrol to the host cell, either in vitro or in vivo, in an amount sufficient to inhibit replication of HSV-1 or HSV-2 within the host cell.
PURPOSE:To obtain a powdery tacky agent, having powerful tackiness and persistent effects thereof and useful for fixing denture bases by combining powder of a polyacrylic, acid salt which is a stringy polymer with powder of a polymer organic acid and powder of a nonstringy polymer which is useful as a food or pharmaceutically acceptable. CONSTITUTION:A tacky agent is obtained by combining powder of a polyacrylate (e.g. Na polyacrylate) with powder of a polymer organic acid (e.g. carboxyvinyl polymer) and powder of a nonstringy polymer (e.g. sodium carboxymethyl cellulose) which is useful as a food or pharmaceutically acceptable as a tackifying ingredient and useful for fixing denture bases. For example, the aforementioned agent has effects on improvement in bonding and fitting of the dentures to gingivae and more stabilized fixing of the denture bases. Tackiness and persistence are excellent by blending the nonstringy polymer with the polymer organic acid and the pH in dissolving is suitable with good feeling of use.
The invention comprises an oxyalkylated phosphatide, the phosphatide prior to oxyalkylation having an iodine number of from 30 to 60 and demonstrating a cloud point of not more than 60 DEG C. The oxyalkylated phosphatide may be obtained by treating a crude phosphatide to separate at least a portion of the hydrogenation catalyst poisons present, hydrogenating the separated phosphatide to an iodine number of from 30 to 60, e.g. by the process described in Specification 825,936, and then reacting the product with an oxyalkylating agent.  The phosphatide may be derived from lecithins, cephalins or sphingomyelins and particularly from crude soybean phosphatide.  Specified oxyalkylating agents are ethylene oxide, propylene oxide, butylene oxide, decene oxide, styrene oxide, epichlorhydrin, glycide, cyclohexene oxide and cyclopentene oxide. The oxyalkyation may be effected in any suitable solvent medium and an aqueous suspension of the phosphatide is suitably used.  The amount of oxyalkylating agent reacted with the phosphatide is preferably such as to raise the pH of a 5% aqueous W/V suspension to from 5,5 to 8,0 and more preferably to from 6,9 to 7,2.  Any excess ethylene oxide (when used) can be expelled from the reaction product by heating to about 80 DEG C. for about 20 minutes.  An example is given for the oxyethylation of a soybean phosphatide (iodine value about 52 and cloud point 32 DEG C.) in aqueous medium using gaseous ethylene oxide in such amount as to increase the initial pH of 5,8 to 6,7. Examples are also given in which cyclohexane or a mixture of cyclohexane and methanol are used instead of water as reaction medium in a similar oxyethylation process and a comparative example is included in which commercial soybean phosphatide is oxyalkylated with ethylene oxide.  The products are suitable as emulsifying agents in oil and water emulsions for parenteral administration (see Group VI). Specification 770,427 also is referred to.ALSO:A fat emulsion suitable for parenteral administration comprises an injectable trigylceride emulsified with water and containing as an emulsifying agent an oxyalkylated phosphatide (especially soybean phosphatide), the phosphatide (prior to oxyalkylation) having an iodine number of from 30 to 60 and demonstrating a cloud point of not more than 60 DEG C. (see Group IV(b)).  The injectable triglyceride is suitably a refined, edible coconut oil and a metabolisable carbohydrate e.g. glucose, and an anti-oxidant e.g. alphatocopherol may also be present. Specifications 770,427 and 825,936 are referred to.
Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
PROBLEM TO BE SOLVED: To obtain a seed oil contg. no glycproteins by treating with an absorbent an org. solvent extract obtd. from Jatropha multifida linne as a Euphorbiaceae plant. SOLUTION: Seeds of Jatropha multifida linne as a Euphorbiaceae plant are pulverized, and then admixed with an org. Solventsuch as n-hexane to be subjected to extraction at about 40 to 50 deg.C for about 1 hour. The resultant extract is conc. under reduced pressure while distilling the solvent off to obtain a seed oil. At least one absorbent selected from among activated clay, activated carbon, Al(OH)3 , etc., is added to the seed oil, which is than stirred under an N2 gas stream at about 40 to 50 deg.C, then cooled, and filtered to obtain a seed oil contg. no substantial toxic glycoproteins. Predetermined amts. of the refined seed oil, a higher alcohol such as centanol or oleyl alcohol, and a surfactant such as a polyoxyethylene higher alcohol ether are then mixed together, and admixed with hot purified water under heat and with stirring to effect emulsification, followed by cooling to obtain a cosmetic perpetration having a good protective effect, such as a hair treatment.
Intracranial atherosclerosis accounts for 10 to 40%, depending on ethnicity, of the 700,000 ischemic strokes in the United States every year.The annual rate of recurrent stroke in patients with optimally treated Intracranial atherosclerosis remains more than twice the average of other stroke etiologies (12.5% vs. 5%).A robust literature has established that vessel wall MRI of extracranial carotid vessel wall enhancement can predict stroke, independent of stenosis. Vessel wall enhancement has been reported in symptomatic intracranial atherosclerosis. Vessel wall enhancement is typically demonstrated by the uptake of gadolinium MRI contrast into the atherosclerotic plaque. A novel MRI contrast agent, ferumoxytol, allows multicontrast weighting on T1w and T2w images and provides important insight into the role of local vessel wall inflammation by accumulating in macrophages on delayed T2\* sequences.

To identify effective prevention and treatment strategies for cerebrovascular disease, the investigator(s) need to critically evaluate vessel wall MRI techniques, determine vessel wall enhancement prevalence, and explore the link between vessel wall enhancement and inflammation. The investigator(s) hypothesize that vessel wall enhancement is reliable, associated with symptomatic Intracranial atherosclerosis. In order to answer our hypotheses, the investigator(s) propose a pilot study on 80 participants. The investigator(s) will opportunistically enroll participants who receive standard of care vessel wall MRI with gadolinium contrast or perform a baseline vessel wall MRI with gadolinium if needed. Intracranial atherosclerosis participants will have a total of 2-3 study vessel wall MRIs. Study MRI #1 will be performed with gadolinium, if a standard of care MRI has not already been performed. Study MRI #2 will be performed 72-78 hours post- using ferumoxytol contrast infusion. Study MRI #3 is a follow-up vessel wall MRI with gadolinium in 1 year.
BACKGROUND: Manual breathing assist technique (MBAT) is a common physical therapy technique used to facilitate airway clearance and improve ventilation and oxygenation. The effects during and immediately after intervention in individuals with chronic obstructive pulmonary disease (COPD) are unknown. This study aimed to investigate the acute effects and potential mechanisms of MBAT on lung volume, dyspnea, and oxygenation in individuals with COPD.
METHODS: This non-randomized quasi-experimental pre-test/post-test study included participants from pulmonary rehabilitation programs at Tagami Hospital (COPD group) and a community exercise program (Healthy group). During a single session, MBAT was applied during the expiration of every breath for 10 minutes. Dyspnea and lung volumes (tidal volume; VT, inspiratory capacity; IC, inspiratory reserved capacity; IRV, expiratory reserve capacity; ERV) were collected at baseline and after MBAT. Pulse oximetry (SpO2), skeletal muscle oxygenation (SmO2), and oxy- and deoxy-hemoglobin (O2Hb and HHb) using near-infrared spectroscopy (NIRS) were collected at baseline, during, and after MBAT. Between-group comparisons were conducted using the Mann-Whitney U-test and chi-square analyses. Within-group changes before and after MBAT were analyzed using the Wilcoxon signed-rank test. The Kruskal-Wallis test was used to detect differences in NIRS variables in each phase and over time.
RESULTS: Thirty participants with COPD, matched for age and sex, were included, with 15 individuals per group. The difference scores of VT, IRV, and IC were significantly higher in the Healthy group than in the COPD group, but improvements in dyspnea and SpO2 were significantly higher in the COPD group. Compared to baseline, ERV decreased significantly in both groups, with dyspnea and SpO2 improving significantly only in the COPD group. Inspiratory accessory muscle ΔO2Hb and ΔHHb were significantly higher and lower (respectively) during MBAT in the COPD group compared to the Healthy group. Additionally, only the COPD group had increased SmO2 during and after MBAT compared to baseline.
CONCLUSIONS: MBAT in patients with COPD had acute physiological effects in reducing dyspnea by facilitating expiration and decreasing the recruitment of accessory respiratory muscles. MBAT may help individuals with COPD reduce dyspnea before exercise therapy in a pulmonary rehabilitation program.
PURPOSE: Vitamin A is related to concentrations of insulin-like growth factor type 1, a protein produced in response to growth hormone, and to increased mobilization of body iron stores. Thus, vitamin A aids in increased hematopoiesis and may be useful in preventing stunting and anemia. This study aimed to identify the association between vitamin A supplementation from the National Vitamin A Supplementation Program instituted in Brazil and stunting and anemia in socially vulnerable Brazilian children.
METHODS: This is a Cross-sectional population-based study. Children aged 6-59 months old, living in favelas of a capital city in the Northeast of Brazil, were included. Sociodemographic variables were collected. Vitamin A supplementation was also evaluated using the child's vaccination card information. Anthropometric and capillary hemoglobin evaluations were performed to identify the presence of stunting and anemia, respectively. The association analysis was performed using Poisson regression with robust variance estimation.
RESULTS: 598 children participated in this study; 11.3% and 55.6% had stunting and anemia, respectively. As for vitamin A supplementation, 59.5% had taken at least one dose of the supplement,and 3.5% were on the complete supplementation scheme. In the adjusted association analysis, vitamin A supplementation decreased the likelihood of children having stunting and anemia by 8% (RP:0.86; 95% IC 0.86-0.98; p = 0.014) and 31% (RP:0.69; 95% IC 0.53-0.89; p = 0.004), respectively. Children who were fully supplemented were 58% (RP:0.42; 95% IC 0.24-0.77; p = 0.008) less likely to have anemia.
CONCLUSION: Thus, vitamin A supplementation is a protective tool against stunting and anemia in children living in a situation of social vulnerability.
The 3 groups, made up of participants with different pathologies and ages, will receive the same intervention (clinical motor and sensory tests and optional TMS). We are studying the difference in results between these groups.
The main action of ketamine, 2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone, is to antagonize the glutamate N-methyl-D-aspartate (NMDA) receptors. In the clinical setting, topical ketamine cream has been used successfully to relieve various pathogenic forms of pain. In addition to its pain-relieving effects, the cream was also reported to have itch-relieving properties in a very limited study. However, its efficacy on itch has not been established, and the mechanism of action remains uncertain. Ketamine cream is used not only by itself, but also in conjunction with other analgesics. One of these is amitriptyline, which may enhance the analgesic effects of ketamine. The aim of this human experimental study is to use the well-characterized anesthetic Ketamine, both alone and in combination with amitriptyline, as a tool to modulate different histaminergic and non-histaminergic itch modalities evoked by histamine and cowhage.
Strong or Moderate CYP3A Inhibitors

Coadministration of TAZVERIK with a strong or moderate CYP3A inhibitor increases tazemetostat plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose [see Dosage and Administration (2.4)].

Strong or Moderate CYP3A Inducers

Coadministration of TAZVERIK with a strong CYP3A inducer decreases tazemetostat plasma concentrations [see Clinical Pharmacology (12.3)], and coadministration of TAZVERIK with a moderate CYP3A inducer may also decrease tazemetostat plasma concentrations. The decrease in tazemetostat plasma concentration may decrease the efficacy of TAZVERIK. Avoid coadministration of moderate or strong CYP3A inducers with TAZVERIK.
PROBLEM TO BE SOLVED: To obtain the subject medicine containing a specific 2,6-di-t-butylphenol derivative as an active ingredient, and expressing a strong cell-protecting action on kidney-originated cells and a strong renal function-improving effect in puromycin nephropathy, etc. SOLUTION: This renal disease medicine contains a compound of formula I  X is O, a group of formula II [(n) is 0-2]; R1 is H, an acyl; R3 is a lower alkyl; R2 is H, R3 , a lower alkenyl; R4 , R5 are each H, a (substituted)alkyl, a (substituted)aryl, etc.; R6 is R4 , formyl, carboxyl, etc.; R3 and R4 may be combined with each other to form a five-membered ring; when the five- membered ring and the benzene ring in the formula form benzofuran, benzo[b]thiophene, etc., R6 does not exit; R5 and R6 may be combined with each other to form a cycloalkyl group, etc.}, its optical active isomer or salt as an active ingredient. The medicine is preferably administered at a daily active ingredient dose of 1-1000mg once to twice a day for an adult by a (non) oral administration method, a sustained release administration method, etc.
The ORBIT (Online Remote Behavioural Intervention for Tics) trial is comparing the effectiveness of two treatments delivered online for children and young people with Tourette Syndrome or Chronic Tic Disorder. Families in England with a child/young person (aged 9-17 years) who experiences tics are being asked to take part. Interested families undergo a telephone screen with a researcher and then asked to complete an online questionnaire. They then attend a screening appointment at either Great Ormond Street Hospital (London) or Queen's Medical Centre (Nottingham).

Families that are eligible and want to take part are randomly allocated to one of two treatments. One treatment uses behavioural therapy (BT), the other involves psychoeducation. Both treatments last for 10-weeks and involve completing online chapters (for the parent and child) with the support of a therapist, there are also some tasks to complete offline. After finishing the treatment, families are asked to complete more questionnaires (at 3, 6, 12 and 18 months after starting the treatment). A smaller sample of families and healthcare professionals are also interviewed about their experience of participation. The study is looking to see if the online delivered treatment may be effective at helping children and young people manage their tics. The study is also exploring whether the online programme is acceptable to families, identifying any problems in getting families to take part/complete the programme and also healthcare professionals' views about the programme. It is important to research online therapy for tics because, at the moment, many people with tics do not get any therapy because there are not enough trained tic therapists. If online delivered treatment is effective, this may mean more children and young people could access tic therapy.
The natural sleep factor combination external agent application system comprises a natural sleep factor combination external agent system and an application system. Many people need to sleep well, hope to sleep well, eliminate fatigue and recover body in time. However, fast-acting hypnotics have dependence or addiction, drug resistance and toxic and side effects, and lead insomniacs to frost on snow. Other various sleep-aiding products or methods have slow effect and high cost, and are not suitable for people. The application of the natural sleep factor combination external preparation: the external preparation application system is used for skin acupuncture point transdermal absorption to stimulate channels and collaterals or nasal mucosa to absorb the sleep factors to adjust cranial nerves and improve sleep. The direct administration of the skin or the nasal mucosa takes effect quickly, the administration is only 0.1 to 10 percent of the oral dosage, the gastrointestinal degradation and liver first-pass of the oral medicine are avoided, the damage to the liver and the kidney is reduced, the side effects of gastrointestinal adverse reaction and the like are prevented, and the sleep quality is improved.
The recommended dosage of efavirenz is 600 mg orally, once daily, in combination with a protease inhibitor and/or nucleoside analogue reverse transcriptase inhibitors (NRTIs). It is recommended that efavirenz be taken on an empty stomach, preferably at bedtime. The increased efavirenz concentrations observed following administration of efavirenz with food may lead to an increase in frequency of adverse reactions [see Clinical Pharmacology (12.3)]. Dosing at bedtime may improve the tolerability of nervous system symptoms [see Warnings and Precautions (5.6) Adverse Reactions (6.1), and Patient Counseling Information (17)]. Efavirenz Tablets 600mg should be swallowed intact with liquid. For patients who cannot swallow tablets, the capsule sprinkle method of administration is recommended [ see Dosage and Administration (2.4)]. 

Concomitant Antiretroviral Therapy 

Efavirenz must be given in combination with other antiretroviral medications [ see Indications and Usage (1), Warnings and Precautions (5.3) Drug Interactions (7.1), and Clinical Pharmacology (12.3)]. 

Dosage Adjustment 

If efavirenz is coadministered with voriconazole, the voriconazole maintenance dose should be increased to 400 mg every 12 hours and the efavirenz dose should be decreased to 300 mg once daily using the capsule formulation (one 200 mg and two 50 mg capsules or six 50 mg capsules).Efavirenz tablets must not be broken. [See Drug Interactions (7.1, Table 5) and Clinical Pharmacology (12.3, Tables 7 and 8)]. 

If Efavirenz is coadministered with rifampin to patients weighing 50 kg or more, an increase in the dose of Efavirenz to 800 mg once daily is recommended [see Drug Interactions (7.1, Table 5) and Clinical Pharmacology (12.3, Table 8)].
Patients receive \[18F\]FTT IV over a few seconds to a minute and then undergo PET/CT scan over 20-30 minutes at baseline and another optional scan 1 week later. During the \[18F\]FTT PET/CT scan patients.